Creative Planning
CNCE

Creative Planning’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Creative Planning’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,000
Closed -$38K – 4397
2014
Q3 		$38K Hold
3,000
– – ﹤0.01% 2118
2014
Q2 		$30K Buy
+3,000
New +$29K ﹤0.01% 2235

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Creative Planning's CNCE Position: Q4 2014 in Review

Creative Planning sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2014, closing a stake of 3,000 shares — an estimated $38K sold.

Creative Planning first reported a position in CNCE in Q2 2014 and held it in 2 quarters. The position peaked at $38K in Q3 2014. 54 funds tracked by Wall St. Rank hold CNCE as of Q4 2014.

  • Creative Planning reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Creative Planning sold 3,000 Concert Pharmaceuticals, Inc. shares in Q4 2014, an estimated $38K.
  • Creative Planning first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 2 quarters.
  • Creative Planning's Concert Pharmaceuticals, Inc. position peaked at $38K in Q3 2014.
  • 54 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2014.

Based on Creative Planning's 13F filing for Q4 2014, filed 29 Jan 2015.